Bayer AG is reportedly seeking investors' approval for a 35% cash call that would bolster its financial reserves against growing litigation. The bio-pharma giant has grappled with legal issues, notably deriving from its Roundup weedkiller product. Despite the current challenges, Bayer is showing signs of improvement with predicted growth starting
FY26, despite recent Q4 losses and a cautious outlook for FY25. Shares fluctuated in response to this news, with some sharp plunges to a 20-year low after disappointing forecasts for 2025 Earnings.
CEO Bill Anderson has called for calm among investors as the company navigates these challenges. Bayer has won a significant US legal victory against Roundup cancer claims, which led to an 11% surge in its shares. Other news includes partnership announcements with companies like
OneMedNet to expand AI Medical Imaging Innovation. The company has also experienced challenges within the crop-science unit leading to lowered earnings guidance. Therefore, investors could view Bayer as a contrarian investment given its legal woes and disappointing forecasts, despite the potential for long-term growth from FY26.
BAYER Stocks News Analytics from Tue, 28 Nov 2023 08:00:00 GMT to Fri, 07 Mar 2025 23:02:42 GMT -
Rating -2
- Innovation -1
- Information 6
- Rumor -2
